Skip to content
by Legal Desire
23 May 2024

Latham & Watkins Advises Sanofi on Co-Exclusive Licensing Agreement With Novavax

Advising firms

Deal team

16 lawyers named
LawyerFirmSeniorityPracticeOffice
Aaron Gardner Lead Latham & Watkins LLP Partner healthcare and life sciences New York
Robert Yeh Latham & Watkins LLP Associate healthcare and life sciences Not stated
Nathan Ajiashvili Latham & Watkins LLP Partner Not stated New York
Kaj Nielson Latham & Watkins LLP Associate Not stated Not stated
Sheen Moaleman Latham & Watkins LLP Associate Not stated Not stated
Andrew Clark Latham & Watkins LLP Partner Not stated Century City
Darryl Steensma Latham & Watkins LLP Counsel Not stated Not stated
Brianna Dollinger Latham & Watkins LLP Associate Not stated Not stated
Michael Sweeney Latham & Watkins LLP Associate Not stated Not stated
Drew O'Sullivan Latham & Watkins LLP Associate Not stated Not stated
Mark Goshgarian Latham & Watkins LLP Associate Not stated Not stated
Gary Mo Latham & Watkins LLP Associate Not stated Not stated
Diana Chung Latham & Watkins LLP Associate Not stated Not stated
Enrique Covarrubias Latham & Watkins LLP Associate Not stated Not stated
Aldrich Huang Latham & Watkins LLP Associate Not stated Not stated
Patrick Chew Latham & Watkins LLP Associate Not stated Not stated

13 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.

REGISTER FREE SIGN IN

Want co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.

Stated terms

Stated value
Not stated
What the figure measures
Not stated
Client
SanofiBuy-side
Counterparties
Novavax (Sell-side)